Herceptin Hylecta

(hyaluronidase-oysk)
Check Coverage Restrictions
Or select your Insurance from the list below:

Dosage & Administration

For subcutaneous use only. HERCEPTIN HYLECTA has different dosage and administration instructions than intravenous trastuzumab products.

Do not administer intravenously.

Do not substitute HERCEPTIN HYLECTA for or with ado-trastuzumab emtansine.

Perform HER2 testing using FDA-approved tests by laboratories with demonstrated proficiency.

The recommended dose of HERCEPTIN HYLECTA is 600 mg/10,000 units (600 mg trastuzumab and 10,000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every three weeks.

Herceptin Hylecta Prescribing Information

Herceptin Hylecta Prior Authorization Resources

Most recent state uniform prior authorization forms

Benefits investigation

Herceptin Hylecta PubMed™ News